NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis $84.59 -1.00 (-1.17%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$84.07▼$86.4550-Day Range$74.43▼$85.8952-Week Range$73.68▼$99.56Volume1.06 million shsAverage Volume1.89 million shsMarket Capitalization$16.06 billionP/E Ratio79.06Dividend YieldN/APrice Target$102.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get BioMarin Pharmaceutical alerts: Email Address BioMarin Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside20.6% Upside$102.00 Price TargetShort InterestHealthy3.93% of Shares Sold ShortDividend StrengthN/ASustainability-2.93Upright™ Environmental ScoreNews Sentiment0.63Based on 30 Articles This WeekInsider TradingSelling Shares$5.21 M Sold Last QuarterProj. Earnings Growth42.50%From $2.00 to $2.85 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.90 out of 5 starsMedical Sector25th out of 936 stocksPharmaceutical Preparations Industry6th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 11 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.93% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently decreased by 11.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.Environmental SustainabilityThe Environmental Impact score for BioMarin Pharmaceutical is -2.93. Previous Next 3.1 News and Social Media Coverage News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for BioMarin Pharmaceutical this week, compared to 7 articles on an average week.Search Interest4 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,209,352.00 in company stock.Percentage Held by InsidersOnly 1.85% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 42.50% in the coming year, from $2.00 to $2.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 79.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.35.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 79.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 156.32.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 1.20. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about BioMarin Pharmaceutical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Read More BMRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMRN Stock News HeadlinesJuly 26 at 7:32 AM | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Receives Hold Rating from Canaccord Genuity GroupJuly 25 at 11:40 AM | markets.businessinsider.comAnalyzing BioMarin’s Position Amid Pfizer’s Emergent Gene Therapy and Projected Market ImpactJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.July 25 at 1:46 AM | americanbankingnews.comBioMarin Pharmaceutical Inc. Expected to Earn FY2024 Earnings of $2.05 Per Share (NASDAQ:BMRN)July 24 at 11:05 PM | markets.businessinsider.comFDA Approves BioMarin Pharma's BRINEURA For Children Under 3 Years With CLN2 Disease July 24 at 4:05 PM | prnewswire.comU.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 DiseaseJuly 24 at 10:55 AM | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)July 24 at 10:55 AM | seekingalpha.comBioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024July 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.July 24 at 5:24 AM | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Lowered by StockNews.comJuly 23 at 8:00 AM | prnewswire.comBioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ETJuly 23 at 5:20 AM | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Receives Overweight Rating from Cantor FitzgeraldJuly 23 at 1:27 AM | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by AnalystsJuly 20, 2024 | benzinga.com$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much TodayJuly 20, 2024 | benzinga.comBiomarin Pharmaceutical (NASDAQ:BMRN) Stock Quotes, Forecast and News SummaryJune 17, 2024 | prnewswire.comBioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone HealthJune 7, 2024 | prnewswire.comBioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 CongressJune 5, 2024 | investorplace.comJune's Biotech Boom: 3 Stocks to Buy for a Summertime SurgeSee More Headlines Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today7/26/2024Next Earnings (Confirmed)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,401Year Founded1997Price Target and Rating Average Stock Price Target$102.00 High Stock Price Target$140.00 Low Stock Price Target$72.00 Potential Upside/Downside+20.1%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)$1.07 Trailing P/E Ratio79.35 Forward P/E Ratio42.45 P/E Growth1.2Net Income$167.65 million Net Margins8.31% Pretax Margin9.60% Return on Equity5.34% Return on Assets3.89% Debt Debt-to-Equity Ratio0.12 Current Ratio2.74 Quick Ratio1.70 Sales & Book Value Annual Sales$2.42 billion Price / Sales6.66 Cash Flow$1.79 per share Price / Cash Flow47.31 Book Value$26.29 per share Price / Book3.23Miscellaneous Outstanding Shares189,880,000Free Float186,367,000Market Cap$16.12 billion OptionableOptionable Beta0.32 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Alexander Hardy (Age 55)President, CEO & Director Comp: $1.72MMr. Brian R. Mueller (Age 50)CFO & Executive VP Comp: $1.07MDr. C. Greg Guyer Ph.D. (Age 62)Executive VP & Chief Technical Officer Comp: $1.11MMr. Jeffrey Robert Ajer (Age 62)Executive VP & Chief Commercial Officer Comp: $1.1MDr. Henry J. Fuchs M.D. (Age 66)Ph.D., President of Worldwide Research & Development Comp: $1.41MMs. Erin Burkhart (Age 45)Group VP & Chief Accounting Officer Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early DevelopmentTraci McCartyGroup Vice President of Investor RelationsMr. George Eric Davis (Age 53)Executive VP, Chief Legal Officer, General Counsel & Secretary Comp: $1.23MMs. Humaira SerajuddinSenior VP & Chief Marketing OfficerMore ExecutivesKey CompetitorsSarepta TherapeuticsNASDAQ:SRPTTeva Pharmaceutical IndustriesNYSE:TEVAMyoKardiaNASDAQ:MYOKReata PharmaceuticalsNASDAQ:RETAMirati TherapeuticsNASDAQ:MRTXView All CompetitorsInsiders & InstitutionsEFG Asset Management North America Corp.Bought 355 shares on 7/26/2024Ownership: 0.041%State of Michigan Retirement SystemBought 45,700 shares on 7/26/2024Ownership: 0.024%AlphaCentric Advisors LLCBought 1,000 shares on 7/26/2024Ownership: 0.009%AMI Asset Management CorpSold 7,080 shares on 7/25/2024Ownership: 0.179%Tranquility Partners LLCBought 5,240 shares on 7/25/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions BMRN Stock Analysis - Frequently Asked Questions How have BMRN shares performed this year? BioMarin Pharmaceutical's stock was trading at $96.42 at the beginning of the year. Since then, BMRN stock has decreased by 12.3% and is now trading at $84.59. View the best growth stocks for 2024 here. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings data on Thursday, February, 22nd. The biotechnology company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.45 by $0.05. The firm's revenue for the quarter was up 20.2% compared to the same quarter last year. What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO? 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend. Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's top institutional shareholders include DNB Asset Management AS (0.54%), Sumitomo Mitsui Trust Holdings Inc. (0.23%), Assenagon Asset Management S.A. (0.19%) and AMI Asset Management Corp (0.18%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Richard A Meier, Jeffrey Robert Ajer, Brian Mueller, George Eric Davis, Charles Greg Guyer, V Bryan Lawlis, Erin Burkhart, Mark J Alles and Dennis Slamon. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX) and Micron Technology (MU). This page (NASDAQ:BMRN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
